Kobayashi Pharmaceutical Co., Ltd.
Kobayashi Pharmaceutical Co., Ltd. Fundamental Analysis
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) shows weak financial fundamentals with a PE ratio of 108.57, profit margin of 2.23%, and ROE of 1.76%. The company generates $166.4B in annual revenue with weak year-over-year growth of -4.53%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 28.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze KBYPF's fundamental strength across five key dimensions:
Efficiency Score
WeakKBYPF struggles to generate sufficient returns from assets.
Valuation Score
ModerateKBYPF shows balanced valuation metrics.
Growth Score
WeakKBYPF faces weak or negative growth trends.
Financial Health Score
ExcellentKBYPF maintains a strong and stable balance sheet.
Profitability Score
WeakKBYPF struggles to sustain strong margins.
Key Financial Metrics
Is KBYPF Expensive or Cheap?
P/E Ratio
KBYPF trades at 108.57 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, KBYPF's PEG of -0.01 indicates potential undervaluation.
Price to Book
The market values Kobayashi Pharmaceutical Co., Ltd. at 1.91 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 18.51 times EBITDA. This signals the market has high growth expectations.
How Well Does KBYPF Make Money?
Net Profit Margin
For every $100 in sales, Kobayashi Pharmaceutical Co., Ltd. keeps $2.23 as profit after all expenses.
Operating Margin
Core operations generate 9.77 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.76 in profit for every $100 of shareholder equity.
ROA
Kobayashi Pharmaceutical Co., Ltd. generates $1.34 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Kobayashi Pharmaceutical Co., Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Kobayashi Pharmaceutical Co., Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
KBYPF converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
108.57
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.91
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.42
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.003
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.47
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How KBYPF Stacks Against Its Sector Peers
| Metric | KBYPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 108.57 | 22.56 | Worse (Expensive) |
| ROE | 1.76% | 1288.00% | Weak |
| Net Margin | 2.23% | -5952.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.81 | Strong (Low Leverage) |
| Current Ratio | 2.47 | 2.41 | Strong Liquidity |
| ROA | 1.34% | -197304.00% (disorted) | Weak |
KBYPF outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Kobayashi Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
3.95%
Industry Style: Defensive, Dividend, Low Volatility
GrowingEPS CAGR
-44.52%
Industry Style: Defensive, Dividend, Low Volatility
DecliningFCF CAGR
-40.95%
Industry Style: Defensive, Dividend, Low Volatility
Declining